Data/hora: 04/06/2024 12:01:36

Provedor de dados: | 56
País: | Brazil
Título: | Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
Autores: | Oliveira,G.A.P.; Costa,E.S.; Freitas,M.S.; Dutra,F.F.; Maia,S.F.; Guerra,M.C.; Tabernero,M.D.; Borojevic,R.; Otazu,I.B.; Silva,J.L.
Data: | 2010-06-01
Ano: | 2010
Palavras-chave: | Chronic myeloid leukemia; Imatinib mesylate; Minimal residual disease; Children.
Resumo: | Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.
Tipo: | Info:eu-repo/semantics/report
Idioma: | Inglês
Identificador: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600009
Editor: | Associação Brasileira de Divulgação Científica
Relação: | 10.1590/S0100-879X2010007500026
Formato: | text/html
Fonte: | Brazilian Journal of Medical and Biological Research  v.43 n.6 2010
Fonte: | info:eu-repo/semantics/openAccess